Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cumulative incidence in competing risks data and competing risks regression analysis.

Haesook T Kim1

  • 1Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. kim.haesook@jimmy.harvard.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|January 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Allogeneic transplant outcomes in T-cell prolymphocytic leukemia: a single-center retrospective study.

Leukemia & lymphoma·2026
Same author

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Transplantation and cellular therapy·2026
Same author

Clinicopathological Characteristics and Survival Outcomes of Gastrointestinal Neuroendocrine Tumors in a Large Safety Net Hospital.

Journal of clinical medicine·2026
Same author

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

Blood advances·2026
Same author

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Blood advances·2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Standard survival analysis methods like Kaplan-Meier are biased for competing risks data. This study details correct methods for analyzing competing risks, crucial in medical research for accurate outcome assessment.

Area of Science:

  • Medical Statistics
  • Biostatistics
  • Epidemiology

Background:

  • Competing risks are prevalent in medical research, particularly in cancer studies where treatment mortality and disease recurrence are key outcomes.
  • Standard survival analysis techniques can yield biased results when applied to data with competing risks.

Purpose of the Study:

  • To discuss and compare methods for competing risks data analysis.
  • To highlight the biases introduced by standard survival analysis in the presence of competing risks.

Main Methods:

  • The article reviews methods for calculating cumulative incidence in the presence of competing risks.
  • It covers techniques for comparing cumulative incidence curves and performing competing risks regression analysis.
  • A hypothetical example and real data are used for comparative analysis.

Related Experiment Videos

Main Results:

  • Standard survival analysis methods (Kaplan-Meier, log-rank test, standard Cox model) produce incorrect and biased results for competing risks data.
  • The source and magnitude of bias from the Kaplan-Meier estimate are specifically detailed.

Conclusions:

  • Accurate analysis of medical research data with competing risks requires specialized methods beyond standard survival analysis.
  • Employing appropriate competing risks methodologies is essential for unbiased estimation and comparison of event incidences.